OR WAIT null SECS
© 2022 MJH Life Sciences and Rheumatology Network. All rights reserved.
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
An overview of treatment advances in rheumatology that may potentially impact the current standard of care for patients with lupus.
March 3rd 2022
Criteria used by rheumatologists to help classify lupus due to its heterogenous manifestation.
Types of patient populations at higher risk for developing more severe forms of lupus.
March 10th 2022
Types of tests used to evaluate patients for signs of lupus or disease progression.
Resources that can help educate patients with lupus about their diagnosis and encourage them to take a more proactive role in self-care.
March 18th 2022
Indications for belimumab, a monoclonal antibody, as therapy for patients with systemic lupus erythematosus.
The rationale for using a newer monoclonal antibody therapy, anifrolumab, to manage patients with systemic lupus erythematosus.
March 24th 2022
The rationale for treating lupus nephritis with novel therapies such as belimumab and voclosporin.
Recommendations for monitoring patients on novel therapies used to manage lupus nephritis and making decisions to taper or stop treatment.
March 31st 2022
Novel therapies in the pipeline that demonstrate potential advantages when used as treatment for systemic lupus erythematosus and lupus nephritis.
Advice to rheumatologists in terms of staying up to date on newer treatment options entering the market for lupus.